Patriot Investment Management Group Inc. Buys New Stake in Danaher Corporation $DHR

Patriot Investment Management Group Inc. bought a new stake in Danaher Corporation (NYSE:DHR) during the 3rd quarter, HoldingsChannel reports. The fund bought 4,262 shares of the conglomerate’s stock, valued at approximately $944,000.

Other hedge funds have also recently added to or reduced their stakes in the company. Veery Capital LLC boosted its position in Danaher by 3.1% during the 3rd quarter. Veery Capital LLC now owns 1,581 shares of the conglomerate’s stock worth $350,000 after acquiring an additional 48 shares during the period. Studio Investment Management LLC increased its holdings in shares of Danaher by 3.3% during the second quarter. Studio Investment Management LLC now owns 1,581 shares of the conglomerate’s stock valued at $302,000 after purchasing an additional 51 shares during the period. JDH Wealth Management LLC increased its holdings in shares of Danaher by 4.5% during the first quarter. JDH Wealth Management LLC now owns 1,264 shares of the conglomerate’s stock valued at $240,000 after purchasing an additional 55 shares during the period. OLD Second National Bank of Aurora raised its stake in shares of Danaher by 0.5% during the first quarter. OLD Second National Bank of Aurora now owns 12,114 shares of the conglomerate’s stock valued at $2,297,000 after purchasing an additional 57 shares in the last quarter. Finally, Adelphi Trust Co raised its stake in shares of Danaher by 2.5% during the third quarter. Adelphi Trust Co now owns 2,365 shares of the conglomerate’s stock valued at $524,000 after purchasing an additional 57 shares in the last quarter. Institutional investors own 79.05% of the company’s stock.

Danaher Stock Performance

Shares of NYSE DHR opened at $231.52 on Friday. Danaher Corporation has a 1 year low of $160.93 and a 1 year high of $242.80. The firm has a market cap of $162.76 billion, a P/E ratio of 41.12, a PEG ratio of 2.82 and a beta of 0.76. The stock has a fifty day moving average price of $213.55 and a two-hundred day moving average price of $195.74. The company has a debt-to-equity ratio of 0.48, a quick ratio of 1.25 and a current ratio of 1.65.

Danaher (NYSE:DHR) last posted its quarterly earnings data on Monday, July 20th. The conglomerate reported $1.94 EPS for the quarter, topping analysts’ consensus estimates of $1.85 by $0.09. The company had revenue of $6.26 billion for the quarter, compared to the consensus estimate of $6.12 billion. Danaher had a return on equity of 11.04% and a net margin of 15.95%. The company’s quarterly revenue was up 5.5% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.77 EPS. Research analysts forecast that Danaher Corporation will post 8.53 EPS for the current fiscal year.

Danaher Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, October 30th. Investors of record on Wednesday, September 30th will be issued a dividend of $0.40 per share. This represents a $1.60 dividend on an annualized basis and a yield of 0.7%. The ex-dividend date of this dividend is Wednesday, September 30th. Danaher’s payout ratio is presently 28.42%.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on DHR shares. Wall Street Zen raised shares of Danaher from a “hold” rating to a “buy” rating in a report on Saturday, October 10th. Barclays increased their target price on shares of Danaher from $230.00 to $255.00 and gave the company an “overweight” rating in a research report on Wednesday, October 7th. Wells Fargo & Company lowered their target price on shares of Danaher from $212.00 to $195.00 and set an “equal weight” rating on the stock in a research note on Wednesday, July 22nd. Royal Bank Of Canada boosted their price target on shares of Danaher from $215.00 to $250.00 and gave the stock an “outperform” rating in a research report on Monday, October 5th. Finally, TD Cowen upped their price target on shares of Danaher from $236.00 to $255.00 and gave the stock a “buy” rating in a research note on Tuesday. Two equities research analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and four have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, Danaher has an average rating of “Moderate Buy” and an average target price of $235.41.

Key Stories Impacting Danaher

Here are the key news stories impacting Danaher this week:

• Positive Sentiment: Danaher and NVIDIA announced an AI collaboration to combine Danaher’s scientific instruments, laboratory workflows, automation technology and software with NVIDIA’s accelerated computing and AI capabilities. The partnership is intended to advance autonomous science and speed drug discovery and other laboratory research. Danaher Collaborates with NVIDIA to Advance Autonomous Science
• Positive Sentiment: Danaher is also preparing to launch its first AI-powered autonomous laboratory, targeted to operate at commercial scale in early 2027. The initiative could support longer-term growth in laboratory automation and strengthen the company’s position in AI-enabled life-science research. How to Invest in AI Drug Discovery
• Positive Sentiment: Multiple Zacks reports say Danaher has a favorable combination of earnings-estimate trends and Earnings ESP, suggesting potential for the company to exceed consensus estimates in its next quarterly report. Danaher has also recently demonstrated earnings momentum, with its latest reported quarter exceeding both EPS and revenue expectations. Will Danaher Beat Estimates Again in Its Next Earnings Report?
• Neutral Sentiment: Danaher is projected to announce earnings on Wednesday. Investors will be watching revenue growth, management’s outlook and whether diagnostics and life-sciences demand support the anticipated improvement in earnings. Danaher Projected to Announce Earnings

Danaher Profile

Danaher Corporation (NYSE: DHR) is a global science and technology company that develops and manufactures products, services and solutions for the life sciences, diagnostics and biotechnology industries. Its offerings help researchers, healthcare professionals and biopharmaceutical manufacturers discover, develop, produce and analyze medicines and other biological products.

The company operates through businesses that provide laboratory instruments, consumables, software and services, including technologies for cell analysis, genomics, protein research, bioprocessing and clinical diagnostics.